Mumbai: Glenmark Pharmaceuticals Ltd said it has started selling the generic copy of Precision Dermatology Inc.’s Locoid Lipocream in the US on Monday.

Glenmark can sell the anti-inflammatory cream for a period of 180 days without competition from other generic drugmakers as it was the first company to file an abbreviated new drug application (ANDA) for the drug. The US Food and Drug Administration approved Glenmark’s ANDA application on 27 September.

The hydrocortisone butyrate cream had annual sales of $36.8 million in the year ended 30 September, according to market researcher IMS Health.

Shares of Glenmark Pharmaceuticals fell 0.22% to 523.95 at 11:05am on BSE, while the exchange’s benchmark Sensex rose 1.44% to 21,299.36 points.